BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson’s Disease with First Patient Enrolled

SUNRISE-PD evaluating the Company's anti-inflammatory, insulin-sensitizing candidate bezisterim in patients with Parkinson's disease who have not been treated with carbidopa/levodopa SUNRISE-PD is one of very few clinical trials for a Parkinson's disease treatment to incorporate a decentralized approach option to allow for remote participation Patient enrollment has commenced, with recruitment being supported by The Michael J. Fox Foundation, Davis Phinney Foundation and The Parkinson's Foundation Topline d ...